Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria

Health Policy

Volumn 108, Issue 1, 2012, Pages 10-18

  Iskrov, Georgi ^a   Miteva Katrandzhieva, Tsonka ^a   Stefanov, Rumen ^a  

^a Clinical and Information Centre for Rare Diseases   (Bulgaria)

Author keywords

Access; Bulgaria; Eastern Europe; Health technology assessment; Orphan drugs; Rare diseases

Indexed keywords

ORPHAN DRUG;

ARTICLE; BULGARIA; CROSS-SECTIONAL STUDY; DRUG APPROVAL; DRUG COST; DRUG LEGISLATION; DRUG MARKETING; DRUG UTILIZATION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; OBSERVATIONAL STUDY; REGISTRATION; REIMBURSEMENT;

BULGARIA; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DRUG COSTS; EUROPEAN UNION; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; ORPHAN DRUG PRODUCTION; REIMBURSEMENT MECHANISMS;

EID: 84867335647     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2012.08.013     Document Type: Article

References (31)

1. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Official journal of the European Union (2004/L 136/1). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do%3Furi=OJ%3AL%3A2004%3A136%3A0001%3A0033%3AEN%3APDF.
2. Medicinal Products in Human Medicine Act. State gazette (13.04.2007/31). http://www.mh.government.bg/Articles.aspx%3Flang=bg-BG%26pageid=380%26categoryid=2996.
3. Council of Ministers. Ordinance on the conditions, rules and procedures for regulating and registering the prices of medicines. State gazette (11.12.2007/104). http://www.lex.bg/bg/laws/ldoc/2135573293.
4. Council of Ministers. Ordinance on the conditions, rules and criteria for inclusion, amendments and/or exclusion of drugs from PDL and the terms and conditions of work of the Commission on PDL. State gazette (21.12.2007/110). http://www.lex.bg/bg/laws/ldoc/2135574508.
5. Ministry of Health. Positive drug list of Bulgaria. http://www.mh.government.bg/Articles.aspx%3Flang=bg-BG%26pageid=384%26categoryid=1355.
6. Ministry of Health. Ordinance 34 from 25 November 2005 on the procedure for payment from the state budget of the medical treatment of the Bulgarian citizens, outside the scope of compulsory health insurance. State gazette (29.11.2005/95). http://www.mh.government.bg/Articles.aspx%3Flang=bg-BG%26pageid=391%26currentPage=4%26categoryid=3547.
7. Ministry of Health. Ordinance 38 from 16 November 2004 on the list of conditions for which home treatment NHIF wholly or partly pays the medicines, medical devices and dietary foods with special medical purposes. State gazette (3.12.2004/106). http://www.mh.government.bg/Articles.aspx%3Flang=bg-BG%26pageid=391%26currentPage=4%26categoryid=3151.
8. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official journal of the European Union (2000/L 18/1). http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf.
9. European Medicines Agency. Register of orphan designations. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages%2Fmedicines%2Flanding%2Forphan_search.jsp%26mid=WC0b01ac058001d12b%26searchkwByEnter=false%26alreadyLoaded=true%26isNewQuery=true%26status=Positive%26startLetter=View+all%26keyword=Enter+keywords%26searchType=Active+Substance.
10. European Medicines AgencyRegister of medicinal products. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp%26mid=WC0b01ac058001d124%26searchTab=%26alreadyLoaded=true%26isNewQuery=true%26status=Authorised%26startLetter=View+all%26keyword=Enter+keywords%26searchType=name%26taxonomyPath=%26treeNumber=%26searchGenericType=generics.
11. Clinical and Information Centre for Rare Diseases. Review of the actual situation and tendencies in the rare diseases field in Bulgaria; 2010. http://raredis.org/pub/RD_Report_01112010_EN.pdf.
12. European project for rare diseases national plan development (EUROPLAN). Selecting indicators to evaluate the achievements of rare diseases initiatives; 2011. http://www.europlanproject.eu/_newsite_986987/Resources/docs/2008-2011_3.EUROPLANIndicators.pdf.
13. Ministry of Health. List of diseases by ICD code, medicinal products by INN name and algorithms for treatment of these diseases under Art. 2, par. 2 of Ordinance (MoH) 34/25.11.2009; 2011. http://www.mh.government.bg/Articles.aspx%3Flang=bg-BG%26pageid=449%26categoryid=3193.
14. National Health Insurance Fund. Requirements for provision of drugs to treat rare diseases in outpatient care; 2011. http://www.nhif.bg/web/guest/150.
15. Kolasa K., Schubert S., Manca A., Hermanowski T. A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland. Health Policy 2011, 102:145-151.
16. Rosenberg-Yunger Z.R.S., Daar A.S., Thorsteinsdóttir H., Martin D.K. Priority setting for orphan drugs: an international comparison. Health Policy 2011, 100:25-34.
17. Drummond M., Wilson D., Kanavos P., Ubel P., Rovira J. Assessing the economic challenges posed by orphan drugs. International Journal of Technology Assessment in Health Care 2007, 23(1):36-42.
18. Denis A., Mergaert L., Fostier C., Cleemput I., Simoens S. A comparative study of European rare disease and orphan drug markets. Health Policy 2010, 97:173-179.
19. de Varax A, Letellier M, Börtlein G. Study on orphan drugs. Alcimed; 2004. http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_1_web_en.pdf.
20. European awareness of rare diseases. Special Eurobarometer 361 (2011). http://ec.europa.eu/health/rare_diseases/docs/ebs_361_en.pdf.
21. Brekke K.R., Königbauer I., Straume O.R. Reference pricing of pharmaceuticals. Journal of Health Economics 2007, 26:613-642.
22. Kaló Z., Muszbek N., Bodrogi J., Bidló J. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy 2007, 80:402-412.
23. Improving access to orphan medicines for all affected EU citizens. Final Conclusions and Recommendations of the EU Pharmaceutical Forum, October 2008. http://ec.europa.eu/pharmaforum/docs/pricing_orphans_en.pdf.
24. Rubinstein Y., Groft S.C., Bartek R., et al. Creating a global rare disease patient registry linked to a rare diseases biorepository database: rare disease-HUB (RD-HUB). Contemporary Clinical Trials 2010, 31:394-404.
25. Kesselman I., Elstein D., Israeli A., Chertkoff R., Zimran A. National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model. Blood Cells, Molecules, and Diseases 2006, 37:46-49.
26. McCabe C., Claxton K., Tsuchiya A. Orphan drugs and the NHS: should we value rarity?. BMJ 2005, 331:1016-1019.
27. Haute Authorité de Santé. Réglement intérieur de la Commission nationale d'evaluation des dispositifs medicaux et des techlogies de santé, 28.09.2010. http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-03/reglement_interieur_cnedimts_adopte_230310_2010-03-24_11-01-28_908.pdf.
28. McCabe C., Tsuchiya A., Claxton K., Raftery J. Orphan drugs revisited. Quarterly Journal of Medicine 2006, 99:341-345.
29. European Platform for Rare Disease Registries (EPIRARE); 2011. http://www.epirare.eu/.
30. Desser A., Gyrd-Hansen D., Olsen J.A., Grepperud S., Kristiansen I.S. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40-67. BMJ 2010, 341:c4715.
31. Bombard Y., Abelson J., Simeonov D., Gauvin F.P. Eliciting ethical and social values in health technology assessment: a participatory approach. Social Science and Medicine 2011, 73:135-144.